Published in Surg Clin North Am on August 20, 2012
Esophageal cancer: A Review of epidemiology, pathogenesis, staging workup and treatment modalities. World J Gastrointest Oncol (2014) 2.27
Barrett's oesophagus: Current controversies. World J Gastroenterol (2017) 0.75
Incidence and predictors of osteoporotic fractures in patients with Barrett's oesophagus: a population-based nested case-control study. Aliment Pharmacol Ther (2017) 0.75
Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med (1999) 17.30
Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med (2009) 10.91
The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst (2005) 8.90
Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med (2011) 8.62
Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol (2008) 7.94
Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology (2001) 5.80
Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. JAMA (2011) 4.74
Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. J Natl Cancer Inst (2011) 4.31
Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol (2001) 4.16
Abdominal obesity and body mass index as risk factors for Barrett's esophagus. Gastroenterology (2007) 3.94
Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology (2003) 3.90
The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology (2006) 3.80
Obesity: a challenge to esophagogastric junction integrity. Gastroenterology (2006) 3.72
A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology (2004) 3.50
Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. Gastroenterology (2011) 3.44
Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study. BMJ (2010) 3.44
Prospective, controlled tandem endoscopy study of narrow band imaging for dysplasia detection in Barrett's Esophagus. Gastroenterology (2008) 3.42
Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med (2003) 3.30
Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology (2002) 3.28
Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. Gastrointest Endosc (2007) 3.23
Metaplastic esophageal columnar epithelium without goblet cells shows DNA content abnormalities similar to goblet cell-containing epithelium. Am J Gastroenterol (2009) 3.18
Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol (2004) 3.15
ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc (2006) 3.12
Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol (2006) 3.06
Receipt of previous diagnoses and endoscopy and outcome from esophageal adenocarcinoma: a population-based study with temporal trends. Am J Gastroenterol (2009) 3.04
Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol (2000) 2.99
Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus. Gastroenterology (2007) 2.86
Clinical practice. Barrett's esophagus. N Engl J Med (2009) 2.83
A systematic review and meta-analysis of the risk of increasing adiposity on Barrett's esophagus. Am J Gastroenterol (2007) 2.79
Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc (2007) 2.77
Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut (1996) 2.75
Abdominal obesity and the risk of Barrett's esophagus. Am J Gastroenterol (2005) 2.60
The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut (2011) 2.51
American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology (2011) 2.50
Esophageal adenocarcinoma in Barrett's esophagus after endoscopic ablative therapy: a meta-analysis and systematic review. Am J Gastroenterol (2009) 2.46
Obesity increases oesophageal acid exposure. Gut (2006) 2.42
Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol (2005) 2.40
A pilot study of the association of low plasma adiponectin and Barrett's esophagus. Am J Gastroenterol (2008) 2.39
The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. Am J Epidemiol (2008) 2.34
Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology (2001) 2.30
Efficacy of radiofrequency ablation combined with endoscopic resection for barrett's esophagus with early neoplasia. Clin Gastroenterol Hepatol (2009) 2.28
Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus. Gastroenterology (2011) 2.27
Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. Clin Gastroenterol Hepatol (2010) 2.24
NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med (2007) 2.23
High-resolution endoscopy plus chromoendoscopy or narrow-band imaging in Barrett's esophagus: a prospective randomized crossover study. Endoscopy (2005) 2.21
Central adiposity and risk of Barrett's esophagus. Gastroenterology (2007) 2.20
Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol (2001) 2.17
Race, ethnicity, sex and temporal differences in Barrett's oesophagus diagnosis: a large community-based study, 1994-2006. Gut (2008) 2.08
New British Society of Gastroenterology (BSG) guidelines for the diagnosis and management of Barrett's oesophagus. Gut (2006) 2.07
Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene (2005) 2.07
Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med (2000) 2.05
The relationship between gastroesophageal reflux disease and its complications with Barrett's esophagus. Am J Gastroenterol (1997) 2.03
Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's esophagus. Am J Gastroenterol (1994) 1.97
Effect of a prior endoscopy on outcomes of esophageal adenocarcinoma among United States veterans. Gastrointest Endosc (2008) 1.96
A cost-utility analysis of ablative therapy for Barrett's esophagus. Gastroenterology (2009) 1.95
Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Hum Pathol (2001) 1.94
The perception of cancer risk in patients with prevalent Barrett's esophagus enrolled in an endoscopic surveillance program. Gastroenterology (2005) 1.91
Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am J Gastroenterol (2010) 1.90
Abdominal obesity and the risk of esophageal and gastric cardia carcinomas. Cancer Epidemiol Biomarkers Prev (2008) 1.89
The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am J Gastroenterol (2000) 1.84
Overutilization of endoscopic surveillance in nondysplastic Barrett's esophagus: a multicenter study. Gastrointest Endosc (2011) 1.82
Magnification chromoendoscopy for the detection of intestinal metaplasia and dysplasia in Barrett's oesophagus. Gut (2003) 1.81
Mortality associated with Barrett's esophagus and gastroesophageal reflux disease diagnoses-a population-based cohort study. Am J Gastroenterol (2005) 1.79
Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence. Aliment Pharmacol Ther (2006) 1.74
Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett's esophagus? A meta-analysis. Am J Gastroenterol (2003) 1.73
Fundoplication and the risk of esophageal cancer in gastroesophageal reflux disease: a Veterans Affairs cohort study. Am J Gastroenterol (2005) 1.72
Clinical and demographic predictors of Barrett's esophagus among patients with gastroesophageal reflux disease: a multivariable analysis in veterans. J Clin Gastroenterol (2001) 1.72
Early diagnosis of columnar-lined esophagus: a new endoscopic diagnostic criterion. Gastrointest Endosc (1987) 1.72
Long-term follow-up and factors predictive of recurrence in Barrett's esophagus treated by argon plasma coagulation and acid suppression. Endoscopy (2002) 1.70
Circumferential and focal ablation of Barrett's esophagus containing dysplasia. Am J Gastroenterol (2009) 1.69
Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study. Gut (2010) 1.68
Prevalence and predictors of recurrent neoplasia after ablation of Barrett's esophagus. Gastrointest Endosc (2009) 1.66
p53 expression in low grade dysplasia in Barrett's esophagus: correlation with interobserver agreement and disease progression. Am J Gastroenterol (2002) 1.58
Familial aggregation of Barrett's oesophagus, oesophageal adenocarcinoma, and oesophagogastric junctional adenocarcinoma in Caucasian adults. Gut (2002) 1.57
Barrett's oesophagus: long-term follow-up after complete ablation with argon plasma coagulation and the factors that determine its recurrence. Aliment Pharmacol Ther (2007) 1.54
Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology (2010) 1.51
Buried metaplasia after endoscopic ablation of Barrett's esophagus: a systematic review. Am J Gastroenterol (2011) 1.50
Hospital volume and hospital mortality for esophagectomy. Cancer (2001) 1.47
Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice. Gastrointest Endosc (1999) 1.45
Association of adiponectin multimers with Barrett's oesophagus. Gut (2009) 1.43
Anthropometric correlates of intragastric pressure. Scand J Gastroenterol (2006) 1.43
Does screening for Barrett's esophagus and adenocarcinoma of the esophagus prolong survival? J Clin Oncol (2005) 1.40
Dysplasia in Barrett's esophagus: limitations of current management strategies. Am J Gastroenterol (2005) 1.37
Predictors of progression in Barrett's esophagus: current knowledge and future directions. Am J Gastroenterol (2010) 1.35
Familiality in Barrett's esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal junction. Cancer Epidemiol Biomarkers Prev (2006) 1.33
Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett's esophagus: a population-based study. Am J Gastroenterol (2011) 1.32
Medication usage and the risk of neoplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol (2009) 1.29
Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus. Gastroenterology (2011) 1.25
Anthropometry and esophageal cancer risk in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev (2009) 1.22
Racial and ethnic disparities in the prevalence of Barrett's esophagus among patients who undergo upper endoscopy. Clin Gastroenterol Hepatol (2007) 1.21
Significance of neoplastic involvement of margins obtained by endoscopic mucosal resection in Barrett's esophagus. Am J Gastroenterol (2007) 1.20
Diagnostic yield of methylene blue chromoendoscopy for detecting specialized intestinal metaplasia and dysplasia in Barrett's esophagus: a meta-analysis. Gastrointest Endosc (2009) 1.19
Adequacy of esophageal squamous mucosa specimens obtained during endoscopy: are standard biopsies sufficient for postablation surveillance in Barrett's esophagus? Gastrointest Endosc (2011) 1.18
Assessment of familiality, obesity, and other risk factors for early age of cancer diagnosis in adenocarcinomas of the esophagus and gastroesophageal junction. Am J Gastroenterol (2009) 1.17
Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett's cancer and high-grade intraepithelial neoplasia. Gastrointest Endosc (2005) 1.15
Tobacco smoking increases the risk of high-grade dysplasia and cancer among patients with Barrett's esophagus. Gastroenterology (2011) 1.14
A segregation analysis of Barrett's esophagus and associated adenocarcinomas. Cancer Epidemiol Biomarkers Prev (2010) 1.13
Endoscopic mucosal resection for high-grade dysplasia and intramucosal carcinoma in Barrett's esophagus: an Italian experience. World J Gastroenterol (2005) 1.10
A meta-analysis of the diagnostic accuracy of esophageal capsule endoscopy for Barrett's esophagus in patients with gastroesophageal reflux disease. Am J Gastroenterol (2009) 1.08
Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med (2009) 10.91
Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. Gastroenterology (2011) 3.44
Pancreatic cyst fluid DNA analysis in evaluating pancreatic cysts: a report of the PANDA study. Gastrointest Endosc (2009) 3.32
Peroral transgastric endoscopic ligation of fallopian tubes with long-term survival in a porcine model. Gastrointest Endosc (2005) 2.98
Alcohol and smoking as risk factors in an epidemiology study of patients with chronic pancreatitis. Clin Gastroenterol Hepatol (2010) 2.46
Single-operator cholangioscopy in patients requiring evaluation of bile duct disease or therapy of biliary stones (with videos). Gastrointest Endosc (2011) 2.30
Alcohol consumption, cigarette smoking, and the risk of recurrent acute and chronic pancreatitis. Arch Intern Med (2009) 2.23
Endoscopic gastrojejunostomy with survival in a porcine model. Gastrointest Endosc (2005) 2.20
Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett's esophagus: results from a US Multicenter Consortium. Gastroenterology (2013) 1.92
Multicenter approach to recurrent acute and chronic pancreatitis in the United States: the North American Pancreatitis Study 2 (NAPS2). Pancreatology (2008) 1.87
Comparative performance of uncoated, self-expanding metal biliary stents of different designs in 2 diameters: final results of an international multicenter, randomized, controlled trial. Gastrointest Endosc (2009) 1.85
An analysis of multiple staging management strategies for carcinoma of the esophagus: computed tomography, endoscopic ultrasound, positron emission tomography, and thoracoscopy/laparoscopy. Ann Thorac Surg (2002) 1.80
A novel safe approach to the peritoneal cavity for per-oral transgastric endoscopic procedures. Gastrointest Endosc (2007) 1.73
Diagnostic performance of EUS for chronic pancreatitis: a comparison with histopathology. Gastrointest Endosc (2007) 1.70
A prospective, blinded study of diagnostic esophagoscopy with a superthin, stand-alone, battery-powered esophagoscope. Am J Gastroenterol (2003) 1.62
Pilot study of the porcine uterine horn as an in vivo appendicitis model for development of endoscopic transgastric appendectomy. Gastrointest Endosc (2006) 1.61
Accuracy of EUS in staging of T4 lung cancer. Gastrointest Endosc (2004) 1.60
Technical outcomes and complications of ERCP in children. Gastrointest Endosc (2004) 1.57
Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol (2013) 1.56
Physical activity is associated with reduced risk of gastric cancer: a systematic review and meta-analysis. Cancer Prev Res (Phila) (2013) 1.53
Chronic calcific pancreatitis: combination ERCP and extracorporeal shock wave lithotripsy for pancreatic duct stones. South Med J (2010) 1.52
Training in small-bowel capsule endoscopy: assessing and defining competency. Gastrointest Endosc (2013) 1.50
Detection of telomerase expression in mediastinal lymph nodes of patients with lung cancer. Am J Respir Crit Care Med (2003) 1.42
Primary cystic neoplasms of the pancreas. Neoplastic disorders of emerging importance-current state-of-the-art and unanswered questions. J Gastrointest Surg (2003) 1.35
Endoscopic ultrasound: a meta-analysis of test performance in suspected biliary obstruction. Clin Gastroenterol Hepatol (2007) 1.33
Cost-effectiveness of screening a population with chronic gastroesophageal reflux. Gastrointest Endosc (2003) 1.31
Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol (2013) 1.29
Predictors of outcome in pancreatic duct disruption managed by endoscopic transpapillary stent placement. Gastrointest Endosc (2005) 1.27
Technical feasibility of endoscopic gastric reduction: a pilot study in a porcine model. Gastrointest Endosc (2007) 1.26
Diagnosis of benign cysts of the mediastinum: the role and risks of EUS and FNA. Gastrointest Endosc (2003) 1.25
Smoking is underrecognized as a risk factor for chronic pancreatitis. Pancreatology (2011) 1.19
Excellence in endoscopy: toward practical metrics. Gastrointest Endosc (2006) 1.15
Factors impacting treatment outcomes in the endoscopic management of walled-off pancreatic necrosis. J Gastroenterol Hepatol (2013) 1.11
EUS-guided fine needle aspiration of the liver: indications, yield, and safety based on an international survey of 167 cases. Gastrointest Endosc (2002) 1.10
Transgastric cholecystectomy: transgastric accessibility to the gallbladder improved with the SEMF method and a novel multibending therapeutic endoscope. Gastrointest Endosc (2007) 1.09
Best practices in endoscopic ultrasound-guided fine-needle aspiration. Clin Gastroenterol Hepatol (2012) 1.09
Endosonographic features predictive of malignancy in mediastinal lymph nodes in patients with lung cancer. Gastrointest Endosc (2010) 1.06
Accuracy of EUS criteria and primary tumor site for identification of mediastinal lymph node metastasis from non-small-cell lung cancer. Gastrointest Endosc (2004) 1.06
Physical and mental quality of life in chronic pancreatitis: a case-control study from the North American Pancreatitis Study 2 cohort. Pancreas (2013) 1.06
Association between calcium sensing receptor gene polymorphisms and chronic pancreatitis in a US population: role of serine protease inhibitor Kazal 1type and alcohol. World J Gastroenterol (2008) 1.04
Biopsy depth after radiofrequency ablation of dysplastic Barrett's esophagus. Gastrointest Endosc (2010) 1.03
Pilot study of transesophageal endoscopic epicardial coagulation by submucosal endoscopy with the mucosal flap safety valve technique (with videos). Gastrointest Endosc (2008) 1.03
Relationship between stent characteristics and treatment outcomes in endoscopic transmural drainage of uncomplicated pancreatic pseudocysts. Surg Endosc (2014) 0.99
Endoscopic ultrasound in lung cancer patients with a normal mediastinum on computed tomography. Ann Thorac Surg (2004) 0.99
Metabolic syndrome as a risk factor for Barrett esophagus: a population-based case-control study. Mayo Clin Proc (2013) 0.99
EUS in patients with surgically altered upper GI anatomy. Gastrointest Endosc (2010) 0.99
Low symptomatic premature stent occlusion of multiple plastic stents for benign biliary strictures: comparing standard and prolonged stent change intervals. Gastrointest Endosc (2010) 0.98
NOTES: Gathering momentum. Gastrointest Endosc (2006) 0.96
Helical CT versus EUS with fine needle aspiration for celiac nodal assessment in patients with esophageal cancer. Gastrointest Endosc (2002) 0.96
EUS-guided FNA of solid pancreas tumors. Gastrointest Endosc Clin N Am (2012) 0.96
Immediate endoscopic closure of colon perforation by using a prototype endoscopic suturing device: feasibility and outcome in a porcine model (with video). Gastrointest Endosc (2006) 0.93
Prospective evaluation of a 3.1-mm battery-powered esophagoscope in screening for esophageal varices in cirrhotic patients. Am J Gastroenterol (2003) 0.93
Detection of occult liver metastases during EUS for staging of malignancies. Gastrointest Endosc (2004) 0.92
Assessment of health state utilities and quality of life in patients with malignant esophageal Dysphagia. Am J Gastroenterol (2004) 0.91
Real-time reverse transcription-PCR detects KS1/4 mRNA in mediastinal lymph nodes from patients with non-small cell lung cancer. Clin Chem (2003) 0.91
Preservation and Incorporation of Valuable Endoscopic Innovations (PIVI) on the use of endoscopy simulators for training and assessing skill. Gastrointest Endosc (2012) 0.90
Advantages and limitations of endoscopic ultrasonography in the evaluation and management of patients with gastrointestinal submucosal tumors: a review. Rev Gastroenterol Disord (2007) 0.89
Widespread EMR: a new technique for removal of large areas of mucosa. Gastrointest Endosc (2004) 0.86
Tele-endoscopy: a way to provide diagnostic quality for remote populations. Gastrointest Endosc (2004) 0.86
Accuracy of EUS for detection of intraductal papillary mucinous tumor of the pancreas. Gastrointest Endosc (2002) 0.86
The expanding role of endoscopic ultrasound in pancreatic disease. Rev Gastroenterol Disord (2006) 0.86
Post-sphincterotomy bleeding after the introduction of microprocessor-controlled electrosurgery: does the new technology make the difference? Gastrointest Endosc (2005) 0.85
Safety of endoscopic mucosal resection for Barrett's esophagus. Am J Gastroenterol (2013) 0.85
The MCP-1 -2518 A/G polymorphism is not a susceptibility factor for chronic pancreatitis. Pancreatology (2006) 0.84
Addendum: BOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia. Am J Gastroenterol (2015) 0.84
Determination of sphincter of Oddi dysfunction in patients with prior normal manometry. Gastrointest Endosc (2003) 0.84
Eagle Claw II: A novel endosuture device that uses a curved needle for major arterial bleeding: a bench study. Gastrointest Endosc (2005) 0.84
Accuracy of esophagoscopy performed by a non-physician endoscopist with a 4-mm diameter battery-powered endoscope. Gastrointest Endosc (2003) 0.84
Natural orifice translumenal endoscopic surgery (NOTES): is it time for introduction to clinical practice? Surgery (2009) 0.83
Endoscopic ultrasound-guided tissue acquisition. Dig Endosc (2013) 0.83
Post-ERCP pancreatitis rates do not differ between needle-knife and pull-type pancreatic sphincterotomy techniques: a multiendoscopist 13-year experience. Gastrointest Endosc (2009) 0.82
Utility of baseline positron emission tomography with computed tomography for predicting endoscopic resectability and survival outcomes in patients with early esophageal adenocarcinoma. J Gastroenterol Hepatol (2013) 0.81
EUS-guided FNA of lung masses adjacent to or abutting the esophagus after unrevealing CT-guided biopsy or bronchoscopy. Gastrointest Endosc (2004) 0.81
EUS-guided biliary drainage: taxing and not ready. Gastrointest Endosc (2013) 0.80
Endoscopic suturing without extracorporeal knots: a laboratory study. Gastrointest Endosc (2005) 0.80
Objective evaluation of a new endoscopic ultrasound processor. Dig Endosc (2013) 0.80
The changing paradigm in EUS-guided tissue acquisition. Gastrointest Endosc Clin N Am (2013) 0.79
Screening for Barrett's esophagus: results from a population-based survey. Dig Dis Sci (2014) 0.79
Are genetic variants in the platelet-derived growth factor [beta] gene associated with chronic pancreatitis? Pancreas (2010) 0.78
Idopathic acute pancreatitis: Is EUS worth doing? Am J Gastroenterol (2002) 0.77
Pancreatic duct stent insertion for functional smoldering pancreatitis. Gastrointest Endosc (2003) 0.77
Diagnostic endoscopy: 2020 vision. Gastrointest Endosc (2006) 0.77
Principles of endosonography and imaging. Gastrointest Endosc Clin N Am (2005) 0.77
The endoscopic transilluminator: an endoscopic device for identification of the proximal jejunum for transgastric endoscopic gastrojejunostomy. Gastrointest Endosc (2006) 0.77
Is esophagoscopy alone sufficient for patients with reflux symptoms? Gastrointest Endosc (2004) 0.77
Robotic endoscopy: a small case series, a giant step for endoscopy. Clin Gastroenterol Hepatol (2012) 0.76
Corrigendum: ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus. Am J Gastroenterol (2016) 0.76
NOTES: Gathering momentum. Surg Endosc (2006) 0.75
Is EUS the answer for dyspepsia? Am J Gastroenterol (2003) 0.75
Is it time to take a pass on the increased number of passes in EUS-FNA? Dig Dis Sci (2013) 0.75
EUS 2008 Working Group document: interventional EUS--a road map for the future. Gastrointest Endosc (2009) 0.75
Prediction of Progression in Barrett's Esophagus Using a Tissue Systems Pathology Test: A Pooled Analysis of International Multicenter Studies. Clin Gastroenterol Hepatol (2022) 0.75
Preface: EUS-guided tissue acquisition. Gastrointest Endosc Clin N Am (2013) 0.75
Novel challenges of multi-society investigator-initiated studies: a paradigm shift for technique and technology evaluation. Surg Endosc (2013) 0.75
Best of DDW 2002. Highlights from the 2002 Digestive Disease Week. May 19-22, 2002, San Francisco, CA. Rev Gastroenterol Disord (2002) 0.75
Carbon Dioxide Insufflation During Endoscopic Pancreatic Function Tests Does Not Alter Duodenal Aspirate Bicarbonate Concentrations. Pancreas (2017) 0.75
Pathology quiz case 3. Heterotopic gastric mucosa (inlet patch). Arch Otolaryngol Head Neck Surg (2011) 0.75
Endoscopic epiglottic mucosal banding as a cause of laryngospasm. Can J Anaesth (2013) 0.75